GlassScriptPhysician profile
Jennifer L Wolfe
NPI 1336926161
$2,087.16
in general payments reported to CMS, 2019-2025
31 companies · $966 in 2025
The $966 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $68.30 · 2024: $1,053 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $346.99 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $221.30 | 2024-2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $153.04 | 2024 | Quviviq |
| Lundbeck LLC | $137.93 | 2023-2025 | Brintellix, Rexulti |
| Abbvie INC. | $115.68 | 2024 | |
| Pfizer INC. | $115.49 | 2024-2025 | |
| Novo Nordisk INC | $105.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.07 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $66.66 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $63.66 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $57.66 | 2024-2025 | |
| Gilead Sciences, INC. | $55.47 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $48.00 | 2023-2024 | Rexulti, Abilify Maintena |
| Corcept Therapeutics | $45.30 | 2024-2025 | Korlym |
| Tris Pharma INC | $45.14 | 2024 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.79 | 2024-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $39.78 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $37.01 | 2025 | Jornay Pm |
| Viiv Healthcare Company | $34.09 | 2024 | Apretude |
| Krystal Biotech INC | $32.07 | 2024 | Vyjuvek |
| Merck Sharp & Dohme LLC | $29.20 | 2024-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Seqirus USA INC | $26.46 | 2025 | Fluad, Flucelvax |
| Organon LLC | $26.07 | 2025 | Nexplanon |
| Astellas Pharma US INC | $24.82 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $24.80 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $21.28 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $19.60 | 2025 | Auvelity |
| Si-Bone, INC. | $19.35 | 2025 | |
| Alkermes, INC. | $18.29 | 2025 | Aristada, Lybalvi |
| Aimmune Therapeutics, INC. | $16.89 | 2025 | Zenpep |
| Corium, LLC | $16.69 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.